VectorY Therapeutics raised €74.5 million ($83.5 million) as part of its Series A to fund antibody gene therapies for neurodegenerative diseases. The company’s lead program, VTx-002, is designed to enable in-brain antibody production, targeting a mechanism intended to overcome challenges of systemic delivery and limited CNS access. The financing matters because gene therapy programs are capital-intensive through process development, preclinical/CMC work and clinical ramp-up. A size-matched Series A typically signals confidence in early data and the strength of the manufacturing and delivery plan. For the market, the raise adds another CNS-focused gene-therapy entrant competing for future trial momentum, partnership attention and talent. The item did not provide trial phase details beyond the lead program description, but it clearly links funding to advancing the platform toward broader clinical development.